

## **UN SYSTEM-WIDE COVID-19**

UNITED NATIONS | DEPARTMENT OF OPERATIONAL SUPPORT



## **STORAGE AND HANDLING**

 The FDA-approved recommendations on storage and handling of Moderna vaccines are published on Moderna's website: https://www.modernatx.com/covid19vaccine-eua/providers/storage-handling

 Moderna COVID-19 Vaccine multiple-dose vials are stored frozen between -50° to -15°C. Vials should be stored in the original carton to protect them from light. Do not store on dry ice or below -

- 10. Once thawed, the Moderna COVID-19 Vaccine can be stored refrigerated between 2° to 8°C for up to 30 days. Do not refreeze once thawed.
- 11. Unpunctured vials may be stored at room temperature between 8° to 25°C for up to 24 hours. After the first dose has been withdrawn, the vial should be held between 2° to 25°C. Vials should be discarded 12 hours after the first puncture. Thawed vials can be handled in room light conditions. Do not refreeze once thawed.

#### LIMIT OF 20 PUNCTURES PER VIAL

12. When extracting only booster doses or a combination of primary series and booster doses, the maximum number of doses that may be extracted from each vial should **not exceed 20 doses**. Do not puncture the vial stopper more than 20 times. If the vial stopper has been punctured 20 times, discard the vial and contents.

#### **GUIDELINES FOR THAWING BEFORE ADMINISTRATION**

- 13. <u>Thawing in refrigerated conditions</u>: Thaw 7.5mL vials between 2° to 8°C for 3 hours. Let each vial stand at room temperature for 15 minutes before administering.
- 14. Alternatively, thaw 7.5mL vials at room temperature between 15° to 25°C for 1 hour and 30 minutes.

## VACCINE ADMINISTRATION

#### INSPECTION

50°C.

- 15. Prior to administration, vials should always be inspected to confirm that liquid is white to off-white. Vaccine may contain white or translucent product related particulates.
- 16. Swirl vial gently after thawing and before each withdrawal. The vaccine comes ready to use once thawed. **Do not shake or dilute**.
- 17. Prior to injection inspect each dose to confirm liquid is white to off-white in colour in both vial and syringe, and verify syringe volume. If dosage is incorrect or discolouration or other particulate matter is present, do not administer the vaccine.

#### **TYPES OF NEEDLES**

18. The Moderna vaccine is a suspension for intramuscular (IM) inject00504A.5 (m)26.2 0.3248h04 50.9 (r)15()





Country team scenarios	Scenario 1: Country team with	Scenario 2: Country team with
(local storage capacity)	frozen storage capacity (-50°C to -	cold/refrigerated storage capacity
	15°C)	(2°C to 8°C)
Shipment from central warehouse	Frozen at -50°C to -15°C	Frozen at -50°C to -15°C
Vaccine receipt	Vials to be stored frozen at -50°C to - 15°C, kept in original cartons to protect from light.	Frozen vials to be thawed in refrigerated conditions at 2°C to 8°C upon receipt. Vials can stay in cartons at 2°C to 8°C.
Storage	<u>Frozen vials</u> : until the Expiration Date. <u>Thawed vials</u> to be stored at 2°C to 8°C degrees for up to 30 days from the day of thawing.	Thawed vials to be stored at 2°C to 8°C degrees for up to 30 days from receipt of the shipment.
Thawing	In a phased manner: for administration or for in-country transportation at 2°C to 8°C. For each vial, the thawing date should be duly recorded.	N/A (all vials thawed upon receipt)
In-country transportation	At -50°C to -15°C if possible. If not, at 2°C to 8°C for up to 12 hrs.	At 2°C to 8°C for up to 12 hrs.
Possible delivery approach	Country team to receive all Moderna vaccines from the Programme in one go and handle the thawing of vials as part of the local campaign until 01 April.	Country team may request staggered delivery from the Programme (two consecutive shipments from the central warehouse), to ensure continuity of usable supply until the Expiration Date on 01 April.

## INFORMATION TO VACCINE RECIPIENTS, PHARMACOVIGILANCE, REPORTING OF ADVERSE EVENTS

- 28. Vaccine recipient must be provided information consistent with the <u>factsheet<sup>2</sup></u> prior to receiving each dose of vaccine including benefits/risks of vaccination. Vaccine recipients must be provided with adverse event reporting instructions.
- 29. Appdfropriate medical treatment to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of the Moderna COVID-19 Vaccine. See <u>DHMOSH guidance<sup>3</sup></u> for reference.
- 30. Adverse events following vaccination that are beyond the normal side effect profile and require treatment are to be recorded as part of the clinic visit for that vaccination in Everbridge. The UN has an obligation to cooperate with the manufacturer with respect to pharmacovigilance and the occurrence of adverse events and safety reports in the administration of the Moderna COVID-19 Vaccine under the Programme.

### **EVERBRIDGE**

31. The Everbridge platform has been updated to allow the recording of individuals' additional doses. The Moderna vaccine type, apt48 Tw1 T arl doses.



32. Further guidance will be published in due course with respect to additional enhancements that are being developed (e.g., "walk-in clinic" functionality) to improve the useability of the platform for local teams, improving visibility and flexibility.

# DESTRUCTION OF USED, EXPIRED OR UNUSABLE VIALS, AND ANCILLARIES

33. Used COVID-19 vaccine vials and ancillary supply should be disposed of according to medical waste management best practices. See guidance here for reference:

https://www.afro.who.int/sites/default/files/2021-05/SOP%20Waste%20management%20of%20Covid-19%20Vaccines%20%281%29.pdf

- 34. Unused vials: Any vial of vaccine that exceeds the shelf life indicated by the manufacturer should be disposed of as **regulated medical waste**.
- 35. The manufacturer recommends the incineration of all unusable vials (e.g., depleted, empty, expired, defective or contaminated vaccine vned te urer 26.1 (ca21.5 ( )0.6 (di)13.6 (3582.1 (ur).6 (h)1 (ur)15.9 (er)15



Annex 2 – SOP on pre-conditioning cooling elements for transportation at -50°C to -15°C

Keep Va-Q-Pads (type -21G) at -25°



Annex 3 – SOPs Preconditioning cooling elements (Va-Q-Tec) for 2°C to 8°C shipments OPTION 1: Keep Va-Q-Pads (type +05G) at 3°C for at least 72 hrs.

va-O-tec AG Alfired Nobel Sitraße 33 LESFORD W. ZUL B 07000 14/3----Tel: +49 (0)931 35 942 -0 ALWAYS THE RIGHT TEMPERATURE www.va-Q-tec.com ಹೆಯ್ ೧೯೯೬ ರಾಗಿ ಇಲ್ಲಿ ಮಾಡಿದ ಇಲ್ಲಿ ಮತ್ತು ಮತ್ತ <u>añd ya-0-orio 43 (or 42 \*040.</u> C. BR DOM A NEW MUSIC CONTRACTOR OF A C AREE she ta ng ng mang na maka sa kao i distance of approximately 15-mm to each other Store the pad bundles in a cool room at a temp erature of - 3.3.0 t.C.F. Shine at load 20 barres  $\sim$ 



OPTION 2: Keep Va-Q-Pads (type +05G) at -20°C for at least 24 hrs. then at 2°C to 8°C for 9 hrs.

va-Q-tec AG	Acter: Shife States Senses	
GG	D-97989 Würzburg	
ATURE	Tel: +49 (0)931 35 942 -0 www.va-Q-tec.com	ALWAYS THE RIGHT TEMPERA
19:20	SO 94 Presenditioning vo. Au	12d torus Q one Afor 12.06 to